Latest Reports

“Convergence” is the term increasingly used to describe the intermingling of disciplines in next-gen academic research facilities. Embodied by today’s moonshot-type initiatives targeting big picture-level discovery, convergence has been dubbed “the next scientific revolution.” It is characterized by collaboration among experts in multiple fields of endeavor tackling the major scientific problems of our time. From a facility perspective, convergence goes beyond the organizational progression that has seen traditional departmental siloes challenged by the move to multidisciplinary, interdisciplinary, and transdisciplinary or clustered research. It brings together many diverse specialties, from biomedicine to engineering to business to law, in a single place.

A new Centralized Research Support Facility (CRSF) at the University of California San Diego (UCSD) has created a host of benefits for the university and its Animal Care Program, including almost $13 million in savings to date, with more savings expected when existing space is reassigned. The project could signal a paradigm shift as available research space shrinks, but consolidation/centralization requires significant operational and cultural shifts.

Combining wireless sensor networks with custom mobile apps to create interactive “sentient buildings” and smart community spaces has the potential to significantly impact the future of facility design in higher education, healthcare, research, and other sectors where increased collaboration and space efficiency are crucial.

Penn Medicine and Novartis have joined forces to create the new Center for Advanced Cellular Therapies (CACT), located atop the Henry Jordan Medical Education Center at the Perelman School of Medicine. Dedicated to finding more effective treatments for cancer using personalized medicine, this first-of-its-kind facility forms the epicenter for research using chimeric antigen receptor (CAR) technology, which enables a patient’s T cells to be removed, reprogrammed, and re-infused into the patient, where they can “hunt” and destroy cancer cells.

After a one-year delay, Congress has passed the 21st Century Cures Act, which includes new funding totaling $4.8 billion for the National Institutes of Health (NIH), $500 million for the Food and Drug Administration (FDA) to bring novel drug therapies and medical devices to market more quickly, and $1 billion to fight the growing opioid crisis. The NIH funding includes $1.8 billion for Vice President Joseph Biden’s “Cancer Moonshot,” $1.6 billion for President Obama’s BRAIN initiative, and additional money earmarked for precision medicine. The Cures Act funding is separate from, and in addition to, annual NIH budget increases. It comes on the heals of a $2 billion increase in NIH funding last year, the largest increase in a decade. If the trend continues, it could result in a need for additional research infrastructure in the form of renovations and new construction.